STVN Overview

Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States.

Wall Street analysts forecast STVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STVN is27.00 USD with a low forecast of 24.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Stevanato Group SpA revenue for the last quarter amounts to 346.48M USD, increased 4.81

Stevanato Group SpA. EPS for the last quarter amounts to 0.17 USD, decreased -5.56

Stevanato Group SpA (STVN) has 6010 emplpoyees as of March 12 2026.

Today STVN has the market capitalization of 4.15B USD.